|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||
| 化学式 | C17H13NO3 |
||||||
| 分子量 | 279.29 | CAS No. | 1048371-03-4 | ||||
| Solubility (25°C)* | 体外 | DMSO | 56 mg/mL (200.5 mM) | ||||
| Water | Insoluble | ||||||
| Ethanol | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM. It is ~27-fold selective against PARP1. |
|---|---|
| in vitro | UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM while inhibiting PARP1 with IC50 of 8 μM. [1] |
| in vivo | In organotypic hippocampal slices, PARP-2 inhibition with UPF-1069 (0.01-1 mM) causes a concentration-dependent exacerbation (up to 155%) of oxygen-glucose deprivation (OGD)-induced CA1 pyramidal cell death. Higher concentrations, acting on both PARP-1 and PARP-2, have no effect on OGD injury. In mouse mixed cortical cells exposed to OGD, UPF-1069 (1-10 mM) significantly reduces post-ischaemic damage. [1] |
| 特徴 | The most selective PARP2 inhibitor available to date. |
| キナーゼアッセイ | PARP-1 and PARP-2 activity assays | |
|---|---|---|
| PARP activity is evaluated by utilizing commercially available recombinant bovine PARP-1 and mouse PARP-2. Briefly, the enzymatic reaction is carried out in 100 mL of 50 mM Tris-HCl (pH 8.0) containing 5 mM MgCl2, 2 mM dithiothreitol, 10 mg sonicatedcalf thymus DNA, 0.2 mCi [adenine-2,8-3H]NAD and recombinant enzyme PARP-1 or PARP-2 (0.03 U per sample). Different concentrations of the putative inhibitors are added, and the mixture is incubated for 1 h at 37℃. The reaction is terminated by adding 1 mL of 10% trichloroacetic acid (w/v) and centrifuged. Pellets are then washed twice with 1 mL of H2O and resuspended in 1 mL of 0.1 M NaOH. The radioactivity incorporated from [adenine-2,8-3H]NAD into proteins is evaluated by liquid scintillation spectrometry. Nuclear extracts for PARP activity assay are prepared from PARP-1-/- and PARP-1+/+ mouse fibroblasts as previouslydescribed. Briefly, immortalized fibroblasts from PARP-1-/- and PARP-1+/+ mice are grown in DMEM supplemented with 2 mM glutamine, 10% bovine serum and antibiotics at 37℃. Nuclear extracts are prepared as follows: 10 cm confluent plates are scraped in 1 mL of homogenization buffer composed of 75 mM sucrose, 225 mM mannitol and 5 mM Tris, pH 7.4 plus 10 mL protease inhibitor cocktail. The cell suspension is homogenized with a Teflon pestle, and the mixture is centrifuged at 600 × g for 5 min at 4℃. The crude nuclear pellet is washed and resuspended in 1 mL of PARP assay buffer (5 mM MgCl2, 2 mM DTT, 50 mM Tris, pH 8) containing 100 mM N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) to fully activate PARP activity. Samples containing 100 mL of the resuspended nuclear pellet are incubated for 60 min at 37℃ in the presence of 35.5 nM 3H-NAD. The reaction is stopped with 1 mL of 10% trichloroacetic acid (w/v), and the mixture is centrifuged at 12 000 × g for 10 min at 4℃. The reaction is terminated by the addition of 1 mL of 10% trichloroacetic acid (w/v), and radioactivity of the suspension is measured by liquid scintillation spectrometry. | ||
| 動物実験 | 動物モデル | Rats deprived of hippocampi. |
| 投薬量 | 0.01-1 mM | |
| 投与方法 | ||
|
| R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation [ Autophagy, 2025, 1-17.] | PubMed: 40143425 |
| ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination [ Cancer Lett, 2025, 613:217505] | PubMed: 39892701 |
| The interplay of TARG1 and PARG protects against genomic instability [ Cell Rep, 2023, 42(9):113113] | PubMed: 37676774 |
| Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells [ Res Sq, 2023, rs.3.rs-2688694] | PubMed: 37066268 |
| Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells [ Res Sq, 2023, rs.3.rs-2688694] | PubMed: 37066268 |
| Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51 [ Cell Death Differ, 2021, 10.1038/s41418-020-00733-4] | PubMed: 33531658 |
| Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. [ J Clin Med, 2020, 30;9(4)] | PubMed: 32235451 |
| Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation [ Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.05.007] | PubMed: 31075269 |
| DNA‑PKcs PARylation regulates DNA‑PK kinase activity in the DNA damage response. [ Mol Med Rep, 2019, 20(4):3609-3616] | PubMed: 31485633 |
| Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks [ Mol Cancer Ther, 2018, 17(10):2206-2216] | PubMed: 29970481 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。